Clinical Trial Update: Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis [Phase 2]

View source ↗

Summary

A Phase 2 prospective trial evaluated rituximab for primary pulmonary alveolar proteinosis; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Alveolar Proteinosis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: East Carolina University | Conditions: Pulmonary Alveolar Proteinosis, Primary Disease | Phase 2 | Status: COMPLETED